Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (October 2022)
18 slides from Revelation Biosciences's investor presentation, Oct 6, 2022
Slide 1: Developing innovative therapeutics to address unmet needs
Developing innovative therapeutics to address unmet needs Corporate Presentation / October 2022 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w
Slide 3: Therapeutic Development Pipeline
Therapeutic Development Pipeline Revelation is developing therapeutics based on modulation of the innate immune response using PHAD Therapeutic Candidate Discovery Preclinical Phase 1 Phase 2 Next Milestone REVTx-100 Initiate Phase 1a/1b study REVTx-200 Readout from PEITHO nonclinical study REVTx-30
Slide 4: PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications
Cytokine induction PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications Revelation has developed propriety formulations and methods of use to deliver phosphorylated hexaacyl disaccharide (PHAD®) to the local intranasal cavity or systemically to treat various diseases PHAD REVTx-1
Slide 5: REVTx-100 For the Prevention of Hospital Associated Infection
REVTx-100 For the Prevention of Hospital Associated Infection
Slide 6: REVTx-100 Program Highlights
REVTx-100 Program Highlights Scientific Rationale Next Step Initiate Ph1a/Ph1b study - Planning in progress Intellectual Property US 11,389,654 (Licensed from Vanderbilt University) Additional related applications anticipated Market Large Market potential: Approximately 3% of hospital patients suffe
Slide 7: Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection
Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection Hernandez, et. al. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. DOI: 10.1097/CCM.0000000000003967 REVTx-100 REVTx-200 REVTx-300 REVTx-99b REVDx-501 Pre-treatment wi
Slide 8: PHADs Impart Protection from Gram Positive Bacterial Infection
Study Design: Mice were pre-treated (24 and 48 hours) with vehicle, MPLA (1 mg/kg), or PHADs (1 mg/kg) prior to infection with S. aureus. All given IV. Bacterial counts assessed 3 days post infection PHADs Impart Protection from Gram Positive Bacterial Infection Pre-treatment with MPLA and PHAD(s) d
Slide 9: REVTx-200 Intranasal Adjunct for Improved Intramuscular Vaccination
REVTx-200 Intranasal Adjunct for Improved Intramuscular (IM) Vaccination
Slide 10: REVTx-200 Program Highlights
REVTx-200 Program Highlights - REVTx-100 REVTx-200 REVTx-300 REVTx-99b REVDx-501 Traditional IM Immunization Alone: Increased systemic antibodies (IgG) Systemic protection Weak mucosal antibodies (IgA) Poor mucosal protection Transmission still active IM Immunization + REVTx-200: Increased systemic
Slide 11: Phase 1 and Phase 2 Clinical Data Supports Mechanism of Action
Phase 1 and Phase 2 Clinical Data* Supports Mechanism of Action MCP-1 and IFN-𝜸 tracked with IP-10 50 µg N: 11 Rate: 27% P: 0.05 Placebo N: 24 Rate: 4% IL-7 PHAD resulted in a higher percentage of subjects with clinically meaningful seroconversion following intranasal viral challenge MCP-1 and…
Slide 12: REVTx-300 For the treatment of chronic kidney diseases
REVTx-300 For the treatment of chronic kidney diseases
Slide 13: REVTx-300 Program Highlights
REVTx-300 Program Highlights Images generated via BioRender REVTx-100 REVTx-200 REVTx-300 REVTx-99b REVDx-501 Chronic organ disease (such as chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH), and myocarditis) are propagated by inflammation, followed by fibrosis, and ultimately loss
Slide 14: REVDx-501 Rapid Testing kit for Intranasal IP-10
REVDx-501 Rapid Testing kit for Intranasal IP-10
Slide 15: REVID: A Rapid Test Kit for Detection of Intranasal IP-10
REVIDTM : A Rapid Test Kit for Detection of Intranasal IP-10 REVDx-501 (REVID™) is a diagnostic device in development for the detection of intranasal IP-10 Intranasal IP-10 is an excellent biomarker for detecting an early active respiratory infection (e.g. SARS-CoV-2, influenza A and B, parainfluenz
Slide 16: Revelation Biosciences
2 REVELATION BIOSCIENCES
Slide 17: Beneficial holders and Cap Table
Beneficial holders Percent George Tidmarsh, M.D., Ph.D. (chairman) 8.9% All other management 6.7% Total management 15.6% 5% or Greater George Tidmarsh, M.D., Ph.D. (chairman) 8.9% AXA IM Prime Impact Fund 8.3% Cap Table Shares Common Stock 23,525,788 Public Warrants (REVBW) 10,511,597 Warrants1 12,0
Slide 18: Thank you!
For more information please visit www.revbiosciences.com Thank you!
Revelation Biosciences — Investor Presentation (October 2022) on 6ix